Fabian Buller

Fabian Buller is the CBO of Neurimmune, a Swiss clinical stage biotech company translating human immune memory into next generation antibody therapeutics. Fabian Buller is an experienced biotech executive with >10 years of professional experience in biotech and pharma. Prior to his position at Neurimmune, Fabian Buller served as Director New Ventures at Johnson & Johnson Innovation as well as Director Business Development of Covagen AG. He was instrumental in securing a number of major Biotech-Pharma deals including M&A transactions and licensing deals with J&J, AstraZeneca, ONO Pharmaceutical and Mitsubishi Tanabe Pharma. Fabian Buller, a chemist by training, holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.